Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Speciality: Oncology


Speaker:

Dr. Vamsi Krishna M | Medical Oncology Consultant Medical Oncologist

Description:

Welcome to this insightful overview on the incidence of lung cancer, with a special focus on ALK-rearranged NSCLC, presented by the esteemed Dr. Vamshi Krishna M. In this video, Dr. Vamshi provides a comprehensive understanding of the prevalence, risk factors, and key statistics associated with lung cancer, while delving deeper into the unique characteristics of ALK-rearranged non-small cell lung cancer (NSCLC). His expertise sheds light on why this specific genetic alteration is critical in diagnosis and treatment, offering valuable insights for medical professionals and researchers alike.

Dr. Vamshi Krishna M further explores the diagnostic challenges and advancements in detecting ALK rearrangements, emphasizing the importance of targeted therapies in improving patient outcomes. He discusses the latest research, treatment protocols, and the evolving landscape of precision medicine in managing ALK-positive NSCLC. This discussion serves as an essential resource for oncologists, pulmonologists, and healthcare practitioners seeking to enhance their knowledge in this specialized area of lung cancer care.

We hope this video provides you with a deeper understanding of ALK-rearranged NSCLC and its significance in modern oncology. Stay tuned for more expert-led discussions and updates on cutting-edge advancements in cancer research and treatment. Don’t forget to watch till the end and subscribe for future informative sessions!
 

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

2.

Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC

3.

Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer

4.

Alkem introduces cetuximab under the trade name Cetuxa in India.

5.

A specific drug combination is being tested in a clinical trial for the deadly brain cancer glioblastoma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot